Sprouts Farmers Market closes $600 million revolving credit facility
Investing.com -- Merck & Co Inc (NYSE:MRK) has started a Phase 3 clinical trial to evaluate its dengue vaccine candidate, the pharmaceutical company announced Thursday.
The study will enroll approximately 12,000 individuals between the ages of 2 and 17 years. Researchers will assess a single dose of V181 for the prevention of dengue caused by any of the four serotypes of the virus, regardless of previous exposure.
This large-scale trial represents a significant step in Merck (NSE:PROR)’s development program for the dengue vaccine candidate as it moves into the final stage of clinical testing before potential regulatory submission.
Dengue fever is a mosquito-borne viral disease that affects millions of people globally each year, with children being particularly vulnerable to severe forms of the illness.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.